In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE Buys Instrumentarium: A Big Deal May Boost Digital Mammography

Executive Summary

The $2 billion acquisition by GE Medical Systems of Helsinki, Finland-based Instrumentarium Corp., the largest medical device deal of 2002, has obvious implications for the patient monitoring market in which both companies have major stakes. The deal also is likely to have a significant future impact on driving the growth of the digital mammography market.

You may also be interested in...



In Women's Health, Hologic Stays Ahead of the Curve

Hologic is garnering more attention these days than it might have in the past because it's just come off an "annus mirabilis." In 2006, Hologic made three vertical acquisitions in the area of breast cancer detection, and it reported stellar financial results. The company is now a market leader in osteoporosis assessment and has an approxmately 50% share of the conventional mammography customer base as well as an early lead in digital mammgoraphy, which is remarkable considering that it is a mid-sized company competing in capital equipment markets against the likes of GE and Siemens.

GE's Personalized Play for Amersham

GE Medical's pending $9.5 billion acquisition of Amersham PLC, while cast in terms of the company's commitment to accelerate progress in personalized medicine, is fundamentally a hard-headed numbers play aimed at maintaining momentum of GE's gargantuan $10 billion medical systems business unit. GE needs healthy businesses oriented towards growing markets to maintain its momentum. And Amersham, with its stable, predictable contrast agent and protein separations businesses fits well into the portfolio. Meanwhile, the personalized medicine play holds mid-to-long term promise.

GE Medical and Amersham Sharpen Their Molecular Image

With a surge in interest in molecular imaging, GE Medical Systems has been on the prowl for new technologies that improve performance of its PET and SPECT systems, so that clinicians can obtain information at the subcellular level. Amersham Health, too, has been been looking for better systems to help improve distribution and performance of its radiopharmaceutical labeling agents. Now the two are joining forces to create a next-generation compound for PET using new, easier-to-use chemistries.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel